Plasma levels of adiponectin are markedly diminished in visceral obesity and states of insulin resistance such as non-alcoholic steatohepatitis (NASH), atherosclerosis and type 2 diabetes mellitus [30,31]. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.